




RealRate

PHARMACEUTICAL 2013

Immune Pharmaceuticals INC
Rank 197 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Immune Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Immune Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 222% points.

The company's Economic Capital Ratio, given in the ranking table, is 43%, being 177% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	1,197
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,801
Liabilities, Non-Current	0
Other Assets	75
Other Compr. Net Income	-2,146
Other Expenses	403
Other Liabilities	7,496
Other Net Income	0
Other Revenues	7,804
Property and Equipment	56
Research and Development	3,400
Selling, General and Administrative Expense	4,607

Output Variable	Value in 1000 USD
Assets	1,328
Liabilities	15,297
Expenses	8,410
Revenues	7,804
Stockholders Equity	-13,969
Net Income	-606
Comprehensive Net Income	-1,679
BaseVar	17,492
ECR before LimitedLiability	-387%
Economic Capital Ratio	43%